You had searched for:
There were no results matching the query.
You can also browse the topics below to find what you are looking for.
Support Services
- Download the Prescription and Service Request Form (PSRF)
- Fax the completed form to Shared Solutions® at 1-844-257-6127
Patients can call 1-800-887-8100, Monday–Friday, 8 am–6 pm CT.
FOCUS was the largest study of its kind (N=838) in patients with inadequate response to 2 or more classes of prior preventive treatments1
Significant reduction in average monthly migraine days compared to placebo after inadequate response to 2 or more classes of preventive treatments (primary endpoint)1
Change from baseline in average monthly mIgraine days during the focus phase 3b study1
Patients who achieved ≥50% reduction in monthly average migraine days1
Percentage of patients achieving ≥50% reduction in average monthly migraine days vs placebo during the 12-week study period (secondary endpoint)1
Results in patients with an inadequate response to anticonvulsants or neurotoxins (exploratory analysis)#
3.8 mean reduction from baseline in monthly average migraine days for both quarterly and monthly arms vs 1.0 for placebo in patients with previous anticonvulsant use2
2.7 and 3.2 mean reduction from baseline in monthly average migraine days for quarterly and monthly arms, respectively, vs 0.2 for placebo in patients who previously used neurotoxins2
#For all exploratory analyses, no determination of statistical significance can be made and no conclusions should be drawn.
Patients experienced a significant reduction in the monthly average number of days using migraine-specific acute headache medication (secondary endpoint)2
Mean reduction of 3.7 days for quarterly dosing and 3.9 days for monthly dosing of migraine-specific acute headache medication use vs 0.6 days with placebo2
